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http:WHAT THIS PAPER ADDS
This paper summarises our experience in the treatment of PGL, in particular the carotid body tumours and
addresses clinical, surgical and genetic issues. In addition, we reviewed the literature and developed feasible
strategies for both treatment and follow-up.Objectives: The aim of the present study was to review treatment results in patients with paraganglioma (PGL) of
the neck presenting as carotid body tumour, long-term follow-up and relevance of genetic testing for succinate
dehydrogenase (SDH)-gene mutations.
Design: Retrospective analysis of prospectively collected data and prospective genetic analysis.
Materials and Methods: Over a 25-year period (1987e2011) 50 patients were operated for 63 PGLs of the neck.
Pre-, intra- and postoperative ﬁndings were analysed. Sanger sequencing was performed for genetic testing of
SDH-gene mutations (SDH B, SDHC and SDHD).
Results: Fifty patients underwent resection of 63 PGLs (62 benign, one malignant) without mortality. Eight
patients underwent preoperative embolisation. Vascular surgical procedures were required in 15 operations
(15/63 ¼ 23.8%). Nerve lesions occurred after 13 operations (13/63 ¼ 20.6%) and were associated with large
tumours. A total of 44 patients are alive after a mean follow-up of 9.8 years.
In 40 patients 17 SDH-gene mutations were detected (17/40 ¼ 42.5%): 14 SDHD mutations, two SDHB mutations
and one rare SDHC mutation.
Conclusion: Surgery for PGL is recommended. All PGL patients should be screened for SDH mutations because it
impacts the individual follow-up strategy. Whereas all PGL patients require annual ultrasound control, mutation
carriers and family members with proven mutations should in addition be regularly examined by magnetic
resonance imaging (MRI) of head, neck, thorax, abdomen and pelvis.
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nating from the neuro-ectoderm, occurring from the skull
base to the pelvic ﬂoor. With an incidence of 0.03% of all
tumours, they are extremely rare. In most cases (w50%)
they are found in the head and neck region, especially as
highly vascularised carotid body (CBT) or glomus tumours in
50%.1 PGLs may also appear as adrenal tumours in the
abdomen or as phaeochromocytoma. In the head and neck
region, they are found at the jugular bulb, the vagal and
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//dx.doi.org/10.1016/j.ejvs.2013.01.018location, patients may notice a slowly growing, painless
lateral neck mass, pulse-like sensations or voice changes. In
the majority of cases the tumours are benign, but in up to
6% malignant.2 Malignancy in PGL is deﬁned by the
conﬁrmation of metastases in non-neuro-ectoderm tissue
such as lymph nodes.3
The carotid body was ﬁrst described by Haller in 1743
and functions as a receptor for blood pressure and oxygen.2
Chronic hypoxia can induce hypertrophy and the result-
ing lesions are referred to as non-heritable or sporadic
tumours.4 Up to 30% of all PGLs are caused by germline
mutations of genes associated with the mitochondrial
succinate dehydrogenase complex (SDHD, SDHB, SDHC or
SDHAF2) and follow autosomal dominant inheritance.5 The
aim of this report is to summarise our clinical experience in
patients with CBTs over the last 25 years. We focussed on
preoperative management, surgical treatment, follow-up
and genetic issues.
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Between 1987 and 2011 a total of 50 consecutive patients
with PGL presented at the Department of Vascular Surgery
at the Medical University Hospital Graz. Their clinical and
operative data were collected prospectively in a special
database (DataEase) and analysed retrospectively.
For the present study all living patients were contacted
and underwent follow-up with physical examination and
ultrasound. After informed consent, a blood sample was
taken for genetic testing on succinate dehydrogenase (SDH)-
gene mutations. This was performed at the Institute for
Human Genetics.
Sequencing was done by cycle sequencing using the ABI
BigDye Terminator Cycle Sequencing Kit according to the
supplier’s protocol and was analysed on an ABI3100 genetic
analyser (both ABI). We sequenced all coding exons and
ﬂanking intronic sequences. Family counselling was offered
if applicable.
The routine preoperative work-up in patients with sus-
pected PGL consisted of careful family history, clinical exami-
nation, duplex ultrasound of the neck, computed tomography
(CT) or magnetic resonance (MR) tomography, angiography
(Fig. 4(a)) or MR angiography. The primary diagnostic proce-
dure depended on the referring institution. The necessity of
preoperative interventional embolisation was assessed by the
operating surgeon and vascular radiologist. Every patient
underwent surgery and postoperative follow-up with physical
examination and duplex ultrasound once a year.
The Shamblin classiﬁcation was used to grade the tumour
size, the tumourevessel relationship and invasion. In group
I the tumour is small and easily resected. Group II includes
tumours adherent to or partially surrounding vessels. Group
III consists of tumours surrounding or encasing the vessels.6
Routine follow-up consisted of clinical evaluation after 4e6
weeks, duplex ultrasound after 1 year and at 12-month
intervals. CT or magnetic resonance imaging (MRI) was per-
formed if new pathological ﬁndings occurred in ultrasound.Figure 1. Intra-operative situs with spread bifurcation and para-
ganglioma (PGL, white arrow) partially resected. CCA Common e
Carotid Artery; ECA e External Carotid Artery; ICA e Internal
Carotid Artery; PGL e Paraganglioma.RESULTS
Between 1987 and 2011 a total of 50 patients (33 female,
17 male; mean age 54.5 years, range 17e80 years) under-
went surgery for PGLs at our institution. A total of 37
patients presented with one unilateral tumour at the
carotid bifurcation (15 on the left side, 22 on the right side),
10 were affected at two sites (nine patients bilateral at the
carotid bifurcation, one patient in the tympanic cavity and
contralateral at the carotid bifurcation). Three patients
suffered from three tumours each. (Two of them had one
tumour in the middle ear and two contralateral CBTs, the
third patient had bilateral CBT’s and one recurrent tumour.)
The patients with PGL in the middle ear were operated at
the Ear, Nose, Throat (ENT) Department.
In total, there were 66 PGLs in the 50 patients: 63 PGLs
presenting as CBTs (including one recurrent tumour) and
three PGLs in the middle ear.
Applying the Shamblin classiﬁcation, there were 13
tumours in group I, 28 in group II and 22 in group III.Preoperative embolisation was performed in eight
patients with a mean tumour diameter of 41.3 mm (range
20e55 mm) and a mean age of 54.9 years (range 31.8e78.8
years). This was to reduce tumour mass and blood ﬂow. One
patient suffered from ipsilateral transient ischaemic attack
during the procedure so the embolisation was not
completed due to neurologic symptoms.
The operative strategy consisted of a standard endar-
terectomy incision along the front border of the sterno-
cleidomastoid muscle under general anaesthesia. The
tumour was excised at the carotid bifurcation using prox-
imal and distal vessel control (Fig. 1) and cross-clamping of
the external carotid artery. Vascular reconstruction was
performed as necessary. Ipsilateral lymphadenectomy
completed the standard operative procedure. The mean age
at ﬁrst operation was 54.4 years (range 17e80 years).
Additional vascular procedures were required in 15
patients as shown in Table 1. Due to severe vessel kinking,
the internal carotid artery was resected and reinserted in
three patients. Two patients were treated by a venous
interposition (reversed saphenous vein). In ﬁve patients,
resection of the external carotid artery was required. In
another two patients, ligation of the common carotid artery
was necessary. Three patients sustained a ligation of the
superior thyroid artery. An enlarged carotid body was an
incidental ﬁnding in another patient during standard
endarterectomy for carotid artery stenosis. Histology after
complete resection showed a PGL.
Nerve palsies occurred after 13 operations (13/
63 ¼ 20.6%) (Table 1). In eight patients the vagal nerve was
resected due to the in-growing tumour. In one patient the
hypoglossal nerve could not be preserved. Two patients
underwent combined resection of the superior laryngeal
and the recurrent laryngeal nerve. In one patient the
hypoglossal nerve was reconstructed successfully by
microsurgery. In the 15 patients undergoing extended
resections and additional vascular procedures, there was no
higher incidence of nerve lesions (2/15 patients ¼ 13.3%).
Figure 2. Colour Doppler ultrasound image of PGL (cross-sectional
view of PGL located between external and internal carotid artery).
Table 1. Nerve lesions and additional vascular procedures compared to maximal tumour diameter.
Affected nerves and vascular procedures Number Tumour diameter
0e29 mm 30e59 mm 60e90 mm
Vagal nerve 8 0 7 1
Hypoglossal nerve 2 0 0 2
Superior laryngeal nerve 2 1 1 0
Recurrent laryngeal nerve 1 1 0 0
Resection and reinsertion ICA 3 3 0 0
Saphenous interposition ICA 2 0 2 0
Ligation CCA 2 0 2 0
Ligation STY 3 1 2 0
Ligation ECA 5 1 4 0
ICA e Internal Carotid Artery.CCA e Common Carotid Artery.STY e Superior Thyroid Artery.ECA e External Carotid Artery.
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complications was required. A 68-year-old male patient
suffered from postoperative ipsilateral transitory ischaemic
attack (TIA) and was transferred to Neurology. Symptoms
resolved completely within 24 hours with no persisting
neurological deﬁcit. Cranial CT scan showed no abnormality.
Histological examination conﬁrmed the diagnosis of para-
ganglioma in all cases. In 40 of our 50 patients genetic
testing was conducted. Out of our tested patients, 17 (17/
40 ¼ 42.5%) showed germline mutations (Table 3). Of
these, 14 had mutations in SDHD, two in SDHB and one in
SDHC. These 17 patients with mutation were at a mean age
of 45.2 (18.2) years (range 17.2e75.7 years) at their ﬁrst
operation. Twelve out of these 17 patients presented with
a second PGL (mean age 51.2 years), and three of them
developed a third tumour (mean age 42 years). Patients
with sporadic tumours were at a mean age of 59.4 (14.6)
(range 33.1e79.9 years); ManneWhitney U Test (age
mutation carriers/age sporadic tumours): p ¼ 0.005.
There is one family with SDHD, a father and two
daughters, expressing the same mutation (c.95C>G). The
one recurrent tumour occurred unilaterally in one daughter
5 years after resection of bilateral PGL. It was diagnosed by
routine follow-up via ultrasound and conﬁrmed by MR
tomography. This family was operated for eight PGLs in
total. No further family relations were detected.
Mutation carriers were screened for phaeochromocy-
toma but none was found in each case. In addition to
routine clinical yearly follow-up all patients were contacted
for additional follow-up and genetic testing. After a mean
follow-up time of 9.8 years (range 1e25 years) 44 patients
are alive (44/50 ¼ 88%). One patient with recurrent tumour
underwent secondary resection 6 years after the ﬁrst
operation. One female patient, operated in 1988, suffered
from a malignant PGL at the age of 52, but was lost at
follow-up. Five patients died due to reasons other than the
PGL between 3 and 13 years postoperatively. One patient
moved abroad and could not be followed up with genetic
testing, but could be personally interviewed by telephone.
Another three patients declined genetic testing.
DISCUSSION
In patients presenting with swelling at the lateral neck,
cranial nerve palsies, voice changes or auditory defects,
a PGL of the neck should be included in the differentialdiagnosis. Careful evaluation of family history regarding
tumours is important. Every patient should undergo precise
clinical examination on both sides of the neck. Imaging
procedures, which include a mandatory ultrasound of soft
tissue and vessels of the neck, and MR tomography
including angiography should be performed. In ultrasound
the tumours appear as a homogeneously hypoechogenic
mass (Fig. 2), and in Doppler ultrasound imaging a multidi-
rectional hypervascularity is the discerning feature (Fig. 3).7
Due to contrast medium enhancement, the tumours give
high intensive signal in MR angiography. Especially in the
T2-weighted images, the spread and displaced carotid
bifurcation appears in a typical ‘goblet deformity’ (Fig. 3).8
In MR imaging the Shamblin groups can be classiﬁed
preoperatively. Information about potentially additionally
needed procedures is possible.
CT can be useful in special questions such as relevant
bony erosions or punctate calciﬁcation in the tumour.7 To
reduce radiation exposure and improve soft-tissue visual-
isation, MR tomography plus angiography should be
preferred to CT.7
The clinical value of embolisation is discussed controver-
sially in the literature.8e10 It can be considered in large
tumours, because hypervascularity can be challenging during
surgery. The effect of embolisation is shown in Fig. 4(a)
and (b).
The risk for neurologic complications such as transient
ischaemic attack (TIA) or stroke caused by angiography or
embolisation is considerable. In our series one of eight
patients (12.5%) developed neurologic complications during
Figure 3. MR Angiography showing a right-sided PGL in an oblique
view with typical goblet deformity of the carotid bifurcation.10
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22 ¼ 13.6%) and Persky et al. (6/47 ¼ 12.8).11,12 In large
tumours the operative resection can be facilitated by preop-
erative embolisation. In our institution the indication for
embolisation is currently discussed between the interven-
tional radiologist and the surgeon in each patient individually
and performed one day before the operation now in patients
with tumours of 3.5 cm maximum diameter and larger.
Complete surgical excision is the aim of any operative
procedure for PGL and is the only curative option.9 Radia-
tion for stopping tumour growth can be discussed in
patients with poor health and high risk for anaesthesia,
patients with Shamblin group IV tumours where nerveFigure 4. a. Pre-embolisation; b. Post-embolisation. Digital sub-
straction angiographies of a 60 year old female patient with
hypervascularised tumour sustained by the external carotid artery.
After embolisation the tumour is almost completely
devascularised.injuries seem to be unavoidable, also in patients declining
operation. The risk for nerve palsies seems to be lower than
that in operation, but there is still a risk especially in
younger patients for development of a malignant tumour
post radiation.9 Operation after radiation can be more
challenging because of soft-tissue alteration and scarring.
This may cause more nerve palsies than operation without
radiation. Tumour doubling time is very slow and lies
between 4 and 14 years; hence conservative treatment,
such as a wait-and-see strategy, can also be discussed in
elderly patients, who are free of PGL symptoms but do have
other co-morbidities.
Our results showed that the incidence of additional
vascular procedures or nerve lesions was signiﬁcantly lower
in mutation carriers (Table 2). This can be partly explained by
the early diagnosis of the contralateral PGL in patients with
SDH mutation. This contralateral PGL in our practice was
operated upon early, explaining the signiﬁcantly different
Shamblin classiﬁcation status between the two groups.
Residual tumour masses can continue to grow and may
cause symptoms again. Ipsilateral lymphadenectomy should
be performed simultaneously to identify malignant
tumours. In these tumours malignancy is not deﬁned by
tumour size, pleomorphism, hypercellularity or mitotic
ﬁgures, but by metastases in non-neuro-endocrine tissue.8
To reduce intra-operative bleeding, temporary clamping
or ligation of the external carotid artery may be required.
The larger the tumour the more the risk for inevitable nerve
lesions or additional vascular procedures increases during
the operation.2 In our group nerve resections were unpre-
ventable in tumours measuring at least 3.5 cm. Therefore
early diagnosis and surgery at tumour diameters <3 cm are
recommended. Treatment in specialised centres with
availability of a vascular surgeon is advisable because the
incidence of vascular reconstructions is more than 25%.
Postoperative monitoring for hypertensive episodes is
recommended. Baroreceptor failure syndrome (BFS) was
described by Toma and Netterville and found in 16%.13,14 It
might occur in patients after bilateral resection of the
glomus caroticum with postoperative acute hypertension
and tachycardia. After operation, none of our patient had
blood pressure above 160 mmHg; no further medication
was necessary.Table 2. Differences between sporadic tumours and tumours in
mutation carriers.
Tumour species Mutation
carrier
[n ¼ 32]
Sporadic
tumours
[n ¼ 34]
Sign
Size 31  10.6 35.1  16.7
n % n %
Embolisation 2 6.3 6 17.6 *
Vascular Procedures 5 15.6 10 29.4 *
Nerve lesions 4 12.5 9 26.5 *
Shamblin A 10 31.3 4 11.8 *
Shamblin B 16 50 13 38.2 *
Shamblin C 6 18.8 17 50 *
Size: mean value  standard deviation; *clinically signiﬁcant.
Table 3. Germline mutations in SDH-genes in 17 PGL patients with SDH mutation.
Gene DNA change Amino acid change Phenotype References
SDHD c.28_33delins12bp p.Val10_Cys11delinsX 2 PGL 21
c.50G>T p.Arg17Leu 2 PGL 22 a
c.95C>G p.Ser32X 2 PGL 23
c.95C>G p.Ser32X 2 PGL 23
c.95C>G p.Ser32X 3 PGL 23
c.95C>G p.Ser32X 3 PGL 23
c.95C>G p.Ser32X 2 PGL 23
c.95C>G p.Ser32X 2 PGL 23
c.242C>T p.Pro81Leu 2 PGL 23,24
c.242C>T p.Pro81Leu 2 PGL 23,25
c.337_340delGACT p.Asp113Metfs*21 3 PGL 25
c.341A>G p.Tyr114Cys 1 PGL 23
c.341A>G p.Tyr114Cys 1 PGL 23
c.341A>G p.Tyr114Cys 2 PGL 23
SDHB c.725G>A p.Arg242His 1 PGL 26
c.725G>A p.Arg242His 1 PGL 26
SDHC c.154_155delCT p.Leu52Valfs*45 1 PGL b
The National Center for Biotechnology Information accession numbers are NM_003002.2, NM_003000.2, NM_003001.3 for SDHD, SDHB
and SDHC.
a Probable pathogenicity.
b Previously not described.
J. Fruhmann et al. 435At conﬁrmation of a PGL by the pathologist, we strongly
recommend genetic testing. Standard clinical predictors,
such as positive family history, preceding pheochromocy-
toma, multiple or malignant tumours or age at diagnosis of
<40 years may not always be reliable, because individuals
with germline mutations may also present as clinically
sporadic appearing PGL.9,13 Our results conﬁrm these
observations because 4 of the 17 mutation carriers had
none of the aforementioned clinical predictors although the
mutation carrier age at ﬁrst operation differed signiﬁcantly
from patients with sporadic tumours. Previously made cost
calculations will have to be reconsidered with the emerging
introduction of next-generation sequencing technologies
into the clinic.13
Previous studies showed that it is possible to ﬁnd patients
subgroups according to clinical features, family history and
special predictors with a high probability of germline muta-
tions, for example, young man with bilateral tumours.15 On
the other hand there are reports that up to 30% of apparently
sporadic PGL are caused by germline mutations.16 Therefore
we will continue to test all our patients.
In order of frequency, SDHD mutation should be tested
ﬁrst, followed by SDHB and SDHC. Hereditary cases can also
be seen in von HippeleLindau disease, multiple endocrine
neoplasia type 2 (MEN 2) or neuroﬁbromatosis.9 Additional
genetic testing for these syndromes and for SDHAF2 needs
to be discussed in patients with negative results for SDHD,
SDHB and SDHC mutation analysis. Parallel to the devel-
opments in genetic testing, also immunohistochemical
methods advanced clearly as described by Barletta and van
Nederveen.17,18 Applied to the tumour samples from the
operation, patients with an immunohistochemical negative
result for SDH mutation would not need to be subjected to
extensive genetic testing. Currently the implementation ofthese immunohistochemical methods is structured at our
centre in cooperation with the department for pathology.
In every patient individual follow-up should be planned,
as suggested in the recent review by Boedeker.9
For patients with sporadic PGL we recommend regular
follow-up with clinical examination and ultrasound of the
neck, primarily every year and in the case of inconspicuous
results of the ultrasound every 5 years.
Mutation carriers should undergo closer regular check-up
with ultrasound and additional MR angiography scans of the
head and neck region, the thorax, the abdomen and the
pelvis because these tumours can occur everywhere at the
vegetative nervous system.9 The ideal follow-up protocol is
currently under discussion and depends on the result of
genetic testing. In the most frequent mutation (SDHD)
complete MR imaging for patients every year is dis-
cussed.9,19 In SDHB, Collins recommended a follow-up
strategy with SDHB radionucleotide screening by 18F-ﬂuo-
rodeoxyglucose positron emission tomography (18F-FDG-
PET) with baseline screen and annually repeated surveil-
lance screening supplemented by annual MR imaging.19CONCLUSION
Early detection of CBTs is beneﬁcial for the operative
outcome and can prevent intra-operative nerve lesions.20
Diagnosis can be reached by ultrasound or MR angiography.
Resection should be performed whenever possible and by
a surgeon who is familiar with the head and neck region
and has the technical options for vascular reconstruction.
Regular follow-ups and genetic analysis are mandatory.
Genetic counselling and examination in families of mutation
carriers are advisable to detect PGL early and prevent
extended resection in large tumours.
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